31 May 2017 - The NICE has issued a positive final appraisal determination recommending Cerdelga (eliglustat) as a first-line treatment for adult patients with type 1 Gaucher disease, a very rare and inherited genetic condition which can be life-threatening in severe cases.

This means that Cerdelga, from French pharma major Sanofi and its specialty care global business unit Sanofi Genzyme, is the first oral treatment for many adults with the condition to be recommended by the NICE, the cost-effectiveness watchdog for England and Wales.

Read The Pharma Letter article